The evaluation of VISA and VRSA in MRSA strains isolated from patients hospitalized at intensive care units in Turkey
Abstract number: P1665
Irmak H., Cesur S., Simsek H., Coplu N., Kilic H., Arslan U., Bayramoglu G., Ozhak Baysan B., Gulay Z., Hosoglu S., Berktas M., Gencer S., Pekcan Demiroz A., Esen B., Karabiber N., Aydin F., Nevzat Yalcin A.
Aim: The aim of this study is to determine whether VISA and VRSA strains are present among MRSA strains isolated from patients hospitalised at intensive care units in 8 cities in 7 geographical regions representative of Turkey and to establish the MIC values of isolated strains for vancomycin, teicoplanin, linezolid, tigecycline, quinupristin-dalfopristin and daptomycin.
Material and Methods: 260 MRSA strains from 8 cities (Ankara, Konya, Antalya, istanbul, Izmir, Diyarbakir, Van and Trabzon) which are representative of 7 geographical regions of Turkey. Wheteher VISA and VRSA are present on MRSA was investigated using vancomycine screening agar method and E-test methods.
The sensitivity of MRSA strains to vancomycin, teicoplanin, linezolid, tigecycline, quinupristin/dalfopristin and daptomycin was determined using E-test method. In statistical evaluation, KruskalWallis test was used. p < 0.05 was considered statistically significant.
Results: VRSA and VISA was detected in none of overall 260 strains. All MRSA strains were 100% sensitive to vancomycin, teicoplanin and linezoide, 99.6% (259/260) was sensitive to daptomycin, 96.9% (252/260) to tigecycline and 95% (246/259) to quinupristin-dalfopristin.
The MIC values of MRSA strains for vancomycin, teicoplanin, linezolid, tigecycline, quinupristin-dalfopristin and daptomycin were significantly different betweeen different cities (p < 0.05).
Conclusion: In the present study, no VRSA and VISA strains were detected in the MRSA strains isolated form intensive care units. The establishment of 3% (8/260) resistance to tigecycline, 0.4% (1/260) resistance to daptomycin and 5% (13/259) resistance to quinupristin/dalfopristin.was striking.
It is our opinion that screening of antibiotic surveillance data in our country at certeain intervals will be benefical in preventing the spread of these strains and determining the correct antibiotic treatment.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|